talactoferrin alpha

Small moleculeexperimental

Clinical trial activity

7 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
4
Phase 3
3
Phase 4
0

Earliest trial started Apr 1, 2008 (NCT00630656)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2008

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • lf00
  • talactoferrin
  • talactoferrin
  • talactoferrin
  • talactoferrin alfa
  • talactoferrin alfa
  • talactoferrin alpha

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01528137Phase 1May 1, 2012Agennix, National Cancer Institute (NCI), Stanford University
NCT01273779Phase 2/Phase 3 (Phase 3)Jun 1, 2011Agennix
NCT00854633Phase 1/Phase 2 (Phase 2)Jun 1, 2009Agennix, National Institutes of Health (NIH)
NCT00706862Phase 3Feb 1, 2009Agennix
NCT00707304Phase 3Nov 1, 2008Agennix
NCT00923741Phase 1Jun 19, 2008National Cancer Institute (NCI)
NCT00630656Phase 2Apr 1, 2008Agennix, Baylor University
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AgennixFor profit6532008
National Cancer Institute (NCI)Government2112008
Baylor UniversityAcademic/Hospital1012008
National Institutes of Health (NIH)Government1012009
Stanford UniversityAcademic/Hospital1112012
5 organizations
Page 1 / 1